Human leukocyte antigen class I and II molecules presenting NY-ESO-1 (79-108) epitopes (HLA/NY-ESO-1 (79-108))

NY-ESO-1 (encoded by the CTAG1B gene) is a prominent cancer-testis antigen expressed in various malignancies but restricted to germ cells in normal tissues (UniProt P12345). The 79-108 amino acid sequence is a highly immunogenic region containing multiple overlapping epitopes presented by both HLA Class I and Class II molecules, such as HLA-A*02:01 and HLA-DPB1*04 (Gnjatic et al., 2006, Adv Cancer Res). This dual presentation allows for the simultaneous activation of both CD8+ cytotoxic T cells and CD4+ helper T cells, which is essential for a coordinated and sustained anti-tumor response. Therapeutic interventions targeting these complexes include TCR-engineered T-cell therapies like Letetresgene autoleucel and various peptide-based or viral vector vaccines (Pollack et al., 2018, J Clin Oncol). These therapies have shown significant clinical promise in treating synovial sarcoma and melanoma, although their application is restricted to patients possessing specific HLA alleles required for peptide presentation.

Other names

NY-ESO-1 79-108 peptide-MHC complexCTAG1B 79-108 epitopesHLA-restricted NY-ESO-1 antigenNY-ESO-1 (79-108) hotspot

T-cell receptor (TCR) mediated recognition of the peptide-MHC complex leading to T-cell activation and tumor cell lysis.